Dr Mitchel Tate
Research Officer
Heart Failure Pharmacology
Baker Heart and Diabetes Institute
Australia
Biography
Dr Mitchel Tate is a Research Officer in the Heart Failure Pharmacology Laboratory. Mitchel graduated with first class honours from Newcastle University (UK) in 2010, before completing a research-driven Master’s programme from Universitat Pompeu Fabra (Barcelona), both in biomedical research. Dr Tate then received a prestigious British Heart Foundation PhD scholarship to study the role of glucagon-like peptide mimetics directly on inflammatory signalling and fibrosis in the setting of diabetic cardiomyopathy at Queen’s University Belfast. In 2016, Dr Tate was recruited by Associate Professor Rebecca Ritchie to the Baker Heart and Diabetes Institute after receiving a Diabetes Australia General Grant to investigate the therapeutic targeting of histone deacytlase 4 (HDAC4) and bone morphogenetic protein 7 (BMP7) signalling using adeno-associated viral gene therapy. Dr Tate is particularly interested in developing and testing novel pharmacological and gene therapeutic agents in the treatment of diabetic complications, with expertise in the heart and kidney. In addition to his research activities, Dr Tate is committed to raising the awareness of diabetes, a disease often dubbed 'the silent killer', and particularly the cardiovascular complications of diabetes. He has been involved in several initiatives with the British Heart Foundation and lately the Baker Institute, including media appearances and interaction with diabetes patients and volunteer fundraisers. He is also passionate for advocating for early career scientists and is an active member of the Baker Institute Early Career Scientist Committee.
Research Interest
Heart Failure Pharmacology
Publications
-
Dr Mitchel Tate,Exendin-4 attenuates adverse cardiac remodelling in streptozotocin-induced diabetes via specific actions on infiltrating macrophages Basic Research in Cardiology 2016; 111(1):1.
-
Dr Mitchel Tate,The nuclear factor (erythroid‑derived 2)‑like 2 (Nrf2) activator dh404 protects against diabetes‑induced endothelial dysfunction Cardiovasc Diabetol 2017; 16(1):33.
-
Dr Mitchel Tate,Are targeted therapies for diabetic cardiomyopathy on the horizon? Clin Sci 2017; 131(10)897–915.
